Sartar Therapeutics

Based in Finland, Sartar Therapeutics is a startup. Its most recent tracked round is Series A. Brouky classifies it under Healthcare & Life Sciences. Brouky records 1 investor associated with the company.

Sartar Therapeutics develops SAR003, a targeted cancer therapy that induces cell death in cancers expressing the PDE3A gene, primarily focusing on gastrointestinal stromal tumors (GIST). SAR003 is supported by orphan drug designations from EMA and FDA and targets hard-to-treat PDE3A-expressing cancers.